US biotech firm Viela Bio raises $250m in Temasek-backed Series A

US biotech firm Viela Bio raises $250m in Temasek-backed Series A

Visual from Viela Bio's website

US-headquartered Viela Bio, an inflammation and autoimmune biotech spinout of AstraZeneca, has raised $250 million in Series A funding backed by Singapore state-owned investment firm Temasek.

In a statement, Viela Bio said the funding round, which was co-led by healthcare-focused investment firm 6 Dimensions Capital, Boyu Capital, and Hillhouse Capital, will allow it to further develop medicines for severe autoimmune diseases.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter